

## Retrospective Study

## Plasma Exchange Therapy in Patients with Complex Regional Pain Syndrome

Enrique Aradillas, MD, Robert J. Schwartzman, MD, John R. Grothusen, PhD,  
Andreas Goebel, MD, PhD, and Guillermo M. Alexander PhD

From: Drexel University College of Medicine, Philadelphia, PA

Address Correspondence:  
Guillermo M. Alexander PhD  
Drexel University College of Medicine  
Dept of Neurology  
245 N. 15th Street  
Mail Stop 423  
Philadelphia, PA 19102  
E-mail:  
guillermo.alexander@drexelmed.edu

Disclaimer: There was no external funding in the preparation of this manuscript.

Conflict of interest: Each author certifies that he or she, or a member of his or her immediate family, has no commercial association (i.e., consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted manuscript.

Manuscript received:

01-07-2015

Revised manuscript received:

03-04-2015

Accepted for publication:

03-07-2015

Free full manuscript:

www.painphysicianjournal.com

**Background:** Complex regional pain syndrome (CRPS) is a severe chronic pain condition that most often develops following trauma. Some investigators have postulated CRPS to be a post-traumatic neuralgia associated with distal degeneration of small-diameter peripheral axons. Intravenous immunoglobulin treatment (IVIg) has been shown to be efficacious in the treatment of painful polyneuropathies. Some CRPS patients have been reported to respond to IVIg. Based on a recent hypothesis proposing an autoimmune etiology for CRPS, we decided to offer plasma exchange therapy (PE) to CRPS patients with a clinical presentation suggestive of a small fiber neuropathy.

**Objectives:** To evaluate the efficacy of PE in a group of CRPS patients with a clinical presentation suggestive of a small fiber neuropathy that were either non-responders or poor responders to their current treatment.

**Study Design:** This is a retrospective case series study of CRPS patients that met the Budapest diagnostic criteria for CRPS and received PE as treatment for their illness between September 2012 and June 2014. Approval for this review was granted by the Drexel University Institutional Review Board.

**Setting:** Drexel University College of Medicine pain clinic

**Methods:** Thirty-three CRPS patients that received PE treatment were retrospectively studied. The workup for these patients consisted of a complete medical and pain evaluation, the completion of the short-form McGill questionnaire, quantitative sensory testing (QST), and skin punch biopsy. The PE protocol was as follows: all patients had a series of PE therapies (range 5 to 11 with a mean of 7.2) performed over a 2 to 3 week period. Following the PE series, the patients had a pain evaluation and completed the short-form McGill questionnaire. Patients that responded to PE were offered maintenance therapy consisting of either weekly PE or other immune modulating agents. In these patients, their pain was evaluated during the maintenance phase.

**Results:** Thirty of the 33 patients demonstrated significant ( $P < 0.01$ ) median pain reduction of 64% following the initial series of PE. Three patients demonstrated no improvement. Twenty-four patients are receiving maintenance therapy, the pain reduction in these patients following the initial PE series has been maintained with either weekly PE ( $n = 15$ ), oral immune modulating agents ( $n = 8$ ), or IVIg ( $n = 1$ ). The remaining 6 patients are not receiving maintenance therapy and their pain has returned to pre-treatment levels. In addition, this study suggests that patients with the greatest loss of small fibers and the greatest temperature sensory deficits are most likely to benefit from PE therapy.

**Limitations:** The major limitation of this study is its retrospective nature which includes non-randomization, non-blinding, and an uncontrolled design.

**Conclusions:** This study shows that PE is effective in a subset of patients with severe long-standing CRPS and that the reduction in pain following the initial series of PE treatments can be maintained on a weekly PE schedule, IVIg, or with other immune modulating drugs. Large, randomized, placebo controlled studies may be required to confirm and expand these results. Such studies may lead to new therapies for this severe life-altering condition.

**Key words:** Complex regional pain syndrome, small fiber neuropathy, plasma exchange, skin punch biopsies, immune modulating therapies

**Pain Physician 2015; 18:383-394**

**C**omplex regional pain syndrome (CRPS) is a chronic pain condition that most often develops following trauma (1). The pathophysiology of chronic neuropathic pain conditions such as CRPS are not fully understood, but evidence suggests a maladaptive response to nervous system damage involving immune and inflammatory pathways as well as abnormalities in both peripheral and central processing of afferent inputs (2,3). At this time, there is no single therapy that wholly addresses the effects of this varied condition (4-6).

Some investigators have postulated CRPS to be a post-traumatic neuralgia associated with distal degeneration of small-diameter peripheral axons (7). We have reported that some CRPS patients demonstrate reduced epidermal nerve fiber density count, consistent with a small fiber neuropathy (SFN) (8). An autoimmune etiology has also been postulated for CRPS (9-11). These investigators have shown that at least half of their patients demonstrate immunoglobulin G (IgG) serum-autoantibodies directed against and activating autonomic receptors (12), and that CRPS serum-IgG, when transferred to mice causes signs of clinical CRPS (13). Intravenous immunoglobulin (IVIG) has been shown to be efficacious in the treatment of painful polyneuropathies and some patients with CRPS have also been reported to respond to IVIG (14-16).

Considering the evidence of immune system involvement in CRPS (9) and the reported positive response to IVIG in some CRPS patients (14), we tested the efficacy of IVIG in 4 refractory CRPS patients that showed reduced epidermal nerve fiber density count, consistent with a SFN. Following IVIG, 3 patients showed little or no improvement, whereas one patient demonstrated a 25% reduction in overall pain level. This patient also tested positive for IgA monoclonal-gammopathy and since plasma exchange therapy (PE) has been shown to be efficacious for this condition in a randomized double-blind trial (17), it was felt that it would be a suitable potential therapy for this patient. PE or plasmapheresis is an extra corporeal therapy that comprises the extraction of the patient's whole blood which is separated into plasma and blood cells. The plasma is removed and replaced with another solution such as human albumin in saline or specially prepared donor plasma. The reconstituted plasma substitute along with the blood cells is then returned to the patient.

Following PE, this patient had a greater than 60% reduction in pain level. Consequently, we decided to offer PE to CRPS patients with a clinical presentation

suggestive of a SFN that were either non-responders or poor responders to their current treatment. This initial report describes our experience with the first 33 CRPS patients from our pain clinic that received PE.

## **METHODS**

This is a retrospective case series study of CRPS patients seen at the Drexel University College of Medicine pain clinic that met the Budapest consensus criteria for CRPS (18) and received PE as treatment for their illness between September 2012 and June 2014. Approval for this review was granted by the Drexel University Institutional Review Board. Patient records were reviewed from which data regarding demographics, CRPS signs and symptoms, duration of illness and response to PE were obtained. The patient's workup consisted of a complete medical and pain evaluation, the completion of the short-form McGill questionnaire (19), quantitative sensory testing (QST), and skin punch biopsy. The QST methods used for the determination of thermal detection thresholds and thermal pain thresholds have been previously described (20).

All patients had a double lumen indwelling central catheter inserted at the subclavian vein through which the PE was performed. During the PE patients continued their medications, no changes were made to their regular dosage, and no new medications were started. For most patients (n = 30) the PE was performed at Hahnemann University Hospital, Philadelphia, PA. For 3 patients PE was performed at medical centers near their home.

The skin punch biopsies were performed using a 3 mm circular puncher, to a depth of 4 mm under standard sterile technique and local anesthesia. The biopsies were taken at the calf and proximal thigh to evaluate epidermal and sweat gland nerve fibers which are often affected in SFNs (21,22). The epidermal nerve fiber density and autonomic fiber count in sweat glands was determined as previously described (22-24).

The PE protocol included a series of PE (approximately 7) performed over a 2 to 3 week period provided that the plasma fibrinogen was greater than 100 mg/dl, the hematocrit greater than 24, and the ionized calcium greater than 1.02 mmol/L. If these conditions were not met, PE was discontinued until the values normalized. Following the initial series, all patients had another pain evaluation and completed the short-form McGill questionnaire. For patients that chose to continue PE, the initial series was followed by twice a week PE for a period of 4 weeks. These patients were then placed on

a maintenance protocol of weekly PE. The patients that elected weekly PE had a pain evaluation and completed the short-form McGill questionnaire during this period.

Statistical Analysis: Paired difference testing was performed with the paired student's t-test for parametric variables and the Wilcoxon signed-rank test for non-parametric variables. Correlation between variables was determined by evaluating the Spearman's rank correlation coefficient (rho). The data was considered significantly different if  $P < 0.05$ . Statistical calculations were performed with SPSS version 20 (IBM SPSS Statistics for Windows, Armonk, NY).

## RESULTS

### Demographics and Disease Characteristics

Thirty-three CRPS patients received PE during the review period. Patient demographics are listed in Table 1 and co-morbidities listed in Table 2. Patients who were septic, could not tolerate central line placement, were hemodynamically unstable, or were allergic to albumin or heparin were not offered PE.

All patients met the Budapest diagnostic criteria for CRPS (18), demonstrated overall pain greater or equal to 6 on a 0 – 10 numerical rating scale (NRS) with duration of disease greater than 2 years and re-

Table 1. Patient demographics.

	Age (years)	Age range	BMI	BMI range	Duration (years)	Duration range	Onset (years)	Onset range	Pain (0 – 10)	Pain range
All Patients (n = 33)	45.7	21 – 67	29.4	17.9 – 41.3	9.7	2 – 23	35.9	14 – 59	8	6 – 10
Males (n = 10)	50.9	32 – 67	31.9	23.5 – 35.8	10.1	3 – 20	40.9	23 – 56	8	7 – 9
Females (n = 23)	43.4	21 – 64	28.3	17.9 – 41.3	9.8	2 – 23	33.7	14 – 59	8	6 – 10

This table lists, for both male and female patients; the number of patients (n), their average age and range in years, and the mean and range for the body mass index (BMI). The race breakdown was 31 Caucasians and 2 African Americans. In addition, the mean and range of the disease duration (years between initiating event and the first plasma exchange) as well as the median and range of the initial numerical rating scale (NRS) pain score.

Table 2. Patient comorbidities.

Case	Painful conditions or procedures exacerbated by pain	Comorbidities that are being actively treated	Reported comorbidities not being actively treated
1	bilateral knee replacement	hypertension, hyperlipidemia	
2	grade i medial collateral ligament sprain-right knee	migraine headaches	postural orthostatic transient tachycardia syndrome, gastroparesis
3			
4		hypothyroidism	
5	lumbar spinal canal stenosis □	diabetes mellitus type 2, hypothyroidism, gastroesophageal reflux, migraine headaches, major depression	
6	lumbar and cervical spinal canal stenosis □	dilated cardiomyopathy, esophageal reflux, hyperlipidemia, hypertension	
7			
8	osteoarthritis of the cervical spine ■	migraine headaches	
9	osteoarthritis of spine, cervical and lumbar ■		
10		leukocytoclastic vasculitis, dermatitis	gastroparesis, postural orthostatic transient tachycardia syndrome
11	lumbar spine osteoarthritis ■, complete tear of anterior cruciate ligament of the left knee	bronchial asthma, chronic active hepatitis c, esophageal reflux, hypothyroidism, systemic lupus erythematosus	
12		major depression	
13	lumbar disc replacement, lumbar spondylosis ■, status post cervical spine fusion at c4-5-6 and c7 fusion ■		
14		hyperthyroidism	irritable bowel syndrome

Table 2 (cont.). *Patient comorbidities.*

Case	Painful conditions or procedures exacerbated by pain	Comorbidities that are being actively treated	Reported comorbidities not being actively treated
15		neurosarcoidosis, migraine headaches, major depression	
16		factor v leiden	
17		thyroid nodule	
18	thrombophlebitis of the left upper extremity	migraine headaches, grave's disease, von willebrand disease, polycystic ovarian syndrome, gastroesophageal reflux	
19	neuroma status post removal, non-healing fractured right 5th metatarsal **		
20	osteoarthritis of the cervical spine ■	migraine headaches, iga polyclonal gammopathy	psotural orthistatic transient tachycardia syndrome, irritable bowel syndrome
21		chronic pancreatitis	
22		hypothyroidism, hypertension	
23		hypertension, chronic obstructive pulmonary disease	interstitial cystitis, gastroparesis
24		hypothyroidism	
25		polyneuropathy, organomegally, endocrinopathy/ edema, m spike and skin changes (poems) syndrome	
26		major depression	gardner-diamond syndrome, osteodystrophy, anterior scleritis, gastroparesis
27		gastroesophageal reflux	gastroparesis
28	osteoarthritis of the cervical spine ■		
29	lumbar spondylosis ■ & radiculopathy □	major depression, migraine headaches	
30	osteoarthritis of spine, cervical and lumbar ■	rapid eye movement sleep disorder, major depression, obstructive sleep apnea	
31		migraine headaches, major depression, hypercholesterolemia	
32		major depression	irritable bowel syndrome
33	osteoarthritis of spine, cervical and lumbar ■		

This table lists patient comorbidities that are being actively treated, comorbidities reported by the patient that are not being actively treated as well as painful conditions or procedures that exacerbated their CRPS pain. The key for the location of the pain due to painful conditions or procedures is \*\* the pain was localized to the dorsum of the foot, □ the pain was axial in nature, ■ the pain was radicular in nature.

sponded poorly to standard treatment. Prior to PE, the level of pain in all of the subcategories of the McGill questionnaire were scored as severe (Table 3). All patients showed decreased sensation to pin-prick and cold temperature in a glove-stocking-shield distribution. Otherwise, the patients were physically healthy and fulfilled the American Society of Anesthesiologists Physical Status Classification Class I or II. The patients did not have a history of substance or drug abuse, psychiatric illness or suspected somatoform pain disorder.

Thirty-two patients reported a clear precipitating event and their symptoms were initially restricted to one extremity. The remaining patient described no precipitating event; the onset of pain was sudden, localized to both feet, with a clear burning quality. In all patients the pain spread beyond the original affected extremity. In one patient the pain spread to the proximal one third of the contralateral extremity. In the remainder 32 patients the pain spread to all 4 extremities.

Twenty-four patients underwent QST, 9 patients

Table 3. Short Form McGill scores.

	Pre (n=33)	95% CI of the mean	Post (n=33)	95% CI of the mean	Maintenance (n=20)	95% CI of the mean
Total Score (0-220)	135.5	111-149.9	45**	37.3-74	33**	24.8-47
Continuous (0-60)	38	29.2-40.6	14**	10.2-21	9**	6.7-13.8
Intermittent (0-60)	37	29.5-40.6	14**	10.5-20.9	10**	5.8-12.9
Neuropathic (0-60)	42	34.2-45.3	10**	10.6-20.9	11.5**	8.8-14.4
Affective (0-40)	20	15.1-25.4	5**	5.2-12.1	2**	2-7.4

This table lists the pre and post short-form McGill median scores and 95% confidence interval of the mean for all 33 patients that received PE. Also included are the scores from the 20 patients that continued with weekly PE maintenance therapy. Statistically significant differences ( $P < 0.01$ ) between groups are denoted as (\*\*).

declined. Twenty-one (87.5%) demonstrated increased thermal detection thresholds. Ten of the 24 patients demonstrated decreased thermal pain thresholds. Nine patients demonstrated both increased thermal detection thresholds and decreased thermal pain thresholds.

A skin biopsy was performed in 26 patients. A skin biopsy was not performed in the remaining 7 for various reasons; 5 felt the procedure would be too painful, one had a previous diagnosis of POEMS syndrome and a positive QST and was felt that a skin biopsy was not required to ascertain a SFN, and in one patient the biopsy was contraindicated due to severe chronic dermatitis. Twenty-one patients had a skin biopsy consistent with a SFN. Twenty had reduced epidermal nerve fiber density and one patient had decrease in sweat glands. In 4 of the 5 patients with a negative skin biopsy, evidence of small fiber dysfunction was supported by QST. In the last patient there was no evidence of small fiber dysfunction/damage on the skin biopsy, however, a QST was not performed in this patient.

In summary, evidence of a SFN was demonstrated in 26 patients, whereas in 7 patients there was insufficient evidence to determine the presence or absence of a SFN. In these 26 patients an extensive work-up was performed to determine its possible etiology. The work-up consisted of blood work to evaluate for diabetes mellitus, liver disease, autoimmune disorders, para-neoplastic syndromes, infectious diseases, and if an inherited condition was suspected a full genetic evaluation. Only one patient showed an abnormal test; this patient had an elevated anti-sulfatide antibody titer.

### Plasma Exchange

The mean number of PEs in the initial series was 7.2 (range 5 – 11). Three patients had 5 treatments, one patient had 6, 24 patients had 7, 2 patients had 8, 2 patients had 10, and one patient 11 treatments.

The initial series of treatments were performed over a 2 week period in 28 patients and over a 3 week period in 5. All PEs were performed with 1.5 plasma exchange volumes. An isotonic solution containing 5% albumin with a sodium content of  $145 \pm 15$  mEq/L was used as the replacement fluid. Of the 30 patients, for whom PE was performed at Hahnemann University Hospital, one was treated as an outpatient; the remainder were admitted and remained in-house for their entire initial treatment. The 3 patients treated at other institutions received PE in an outpatient setting.

During the PE, the first reported improvement was an increase energy level usually before the third PE session. Prior to any report of decreased pain, patients reported improvement in morning joint stiffness, muscle spasms, and muscle contractions, especially at night time. In addition, decreased sensitivity to touch was described by some patients.

Following PE, the patients demonstrated a statistically significant reduction in their pain level ( $P < 0.001$ ). Only 3 patients demonstrated no improvement. The remaining 30 patients demonstrated a NRS median pain reduction of 64%, and in each case the reduction was at least 2 NRS points (Fig. 1). The NRS pain score throughout the initial 7 exchanges, for the 30 patients where such data was available, is illustrated in Fig. 2. The 3 non-responders did not show any change in their daily NRS pain score (Fig. 2A). The patients that responded to PE showed a progressive decrease in their pain that reached statistical significance by the third PE and continued to improve throughout the therapy (Fig. 2B). In the 30 patients that responded to PE therapy, there was no significant difference ( $P > 0.05$ ) in the degree of pain reduction between punch biopsy positive and negative patients or between QST positive and negative patients. However, there was a significant correlation ( $\rho = 0.558$ ,  $P = 0.009$ ) between pain reduction following PE and increased temperature detection thresholds.

There was also a trend between efficacy and loss of small fibers but the correlation was not significant ( $\rho = 0.203, P > 0.05$ ). The correlation results suggest that patients with the greatest loss of small fibers and the

greatest temperature sensory deficits are most likely to benefit from PE therapy.

Patients also reported improvement in cognitive abilities, joint stiffness, allodynia, generalized malaise, muscle spasm/jerk, and cramps as well as autonomic manifestations such as edema, erythema, and diaphoresis. The decreased sensation to cold and pin-prick remained unchanged in all patients. Two of the 3 patients that didn't respond to PE reported some changes in their CRPS symptoms. One patient reported improved mobility, less stiffness, and less sensitivity to touch. One patient reported that following a pain flare, symptoms that in the past accompanied a flare (painful bruising, redness, temperature changes, sweating, and swelling) were greatly diminished. The third patient reported no symptom changes.

The short-form McGill scores are tabulated in Table 3. The scores before and after PE showed a similar pattern as the NRS pain scores. The 30 patients that responded to PE demonstrated a median reduction of the total McGill score of 64% (range from 38 to 100%). The subcategories of the McGill score followed a similar pattern, with the neuropathic component demonstrating the greatest (76%) decrease. The 3 patients that didn't respond to PE showed no improvement on their McGill scores.

Results of the complete blood count and fibrinogen plasma concentration before and after the initial series of PE in patients that received PE at Hahnemann University Hospital are shown in Table 4. These patients demonstrated statistically significant decreases ( $P < 0.01$ ) in blood RBC counts, Hg, Htc, and fibrinogen. There was a significant correlation ( $\rho = 0.536, P = 0.008$ ) between the change in plasma fibrinogen level and the percent reduction in pain following treatment (Fig. 4). In addition, there were small but statistically significant increases ( $P < 0.05$ ) in the Red Cell Distribution Width (RDW) and White blood cells (WBC).

### PE Maintenance

Following the initial series, 20 of the 33 patients elected to continue PE. These patients received twice a week PE for 4 weeks and continued on a weekly PE schedule. The 20 patients on weekly PE retained significant reduction in pain as compared to pre therapy levels ( $P < 0.01$ ) in both the NRS pain score (Fig. 3) and all components of the McGill questionnaire ( $P < 0.01$ ) (Table 3). These patients have maintained the improvement in pain levels for an average of 5.4 months (range one to 16 months). In addition to decreased pain, 3 of




Fig. 1. Numerical rating scale (NRS) pain score prior to and following the initial series of plasma exchange therapies (PE) for all 33 patients.




Fig. 2. NRS pain scores prior to PE, during the first 7 therapies and after the initial series of therapies. [A] NRS pain scores (mean + se) in the 3 patients that did not demonstrate improvement following PE. [B] NRS pain scores (mean + se) in the patients that showed improvement following PE. (\* $P < 0.001$ , \*\* $P < 0.0001$ )





Fig. 3. NRS pain scores (median and 95% confidence intervals) before and after PE as well as during the weekly PE maintenance treatment phase (\* $P < 0.01$ ).

Fig. 4. This figure illustrates the relationship between the change in plasma fibrinogen and the percent reduction in pain following the initial series of plasma exchanges.

Table 4. Blood parameters pre and post the initial series of plasma exchanges.

	WBC (x103 /mL)	RBC (x106 /mL)	Hg (g/dl)	Htc (Percent)	MCV (fL/cell)	MCH (pg/cell)	MCHC (g/dl)	RDW (percent)	Fibrinogen (mg/dl)
Pre PE	7.10	4.06	12.27	36.46	89.96	30.23	33.60	13.82	250.96
Post PE	7.94*	3.47**	10.53**	31.50**	91.08	30.39	35.90	14.50*	160.54**

The data list blood parameters from the patients that received PE at Hahnemann University Hospital. The abbreviations are as follows: white blood cells (WBC), red blood cells (RBC), hemoglobin (Hg), hematocrit (Htc), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW). Statistically significant changes between pre and post blood values are denoted as (\*)  $P < 0.05$  and (\*\*)  $P < 0.01$ .


these 20 patients were able to completely discontinue opiates (transdermal fentanyl patch, hydromorphone, and oxycodone) and 2 patients are able to walk without the need of their assisting devices (a 4 point walker and a single leg scooter).

### Maintenance with Oral Immunotherapy

Eight patients that responded to PE are currently on oral immunosuppressants. Seven patients (including 5 that were for a time on PE maintenance therapy) decided to discontinue PE. Five patients discontinued PE because they found the maintenance of the Permacath difficult. Two patients that lived outside the Philadelphia area could not find local hospitals that were able to provide the maintenance PE treatments. When PE was discontinued, their pain gradually (over 6 weeks) returned to pre-treatment values. Given the positive response to PE and the fact that their pain had returned

to pre-PE levels we decided to offer them oral immunotherapy. Five patients were placed on mycophenolate mofetil under our care, and one patient was started on adalimumab under the care of her local physician. The patients on mycophenolate mofetil were closely monitored for side effects and titrated to a dose of 1500 mg twice a day over the course of 2 weeks. The reduction in pain level following PE, which had been lost when the therapy was discontinued, has been regained with both adalimumab and mycophenolate mofetil treatment. One patient was placed on prednisone 10 mg daily by the patient's rheumatologist. The reduction in pain level following PE has also been regained on prednisone therapy.

One patient had been taking 4 mg of dexamethasone daily for leukocytoclastic vasculitis. The dexamethasone did not provide any relief of the pain symptoms. Following PE the patient continued all pre-



vious medications, including dexamethasone at the same 4 mg/day dose, and the pain level has remained at a 4 for the last 11 months without any additional medication.

In the 8 patients on immunotherapy, the median pain level is 4 (range 3 to 6) which is significantly less ( $P < 0.01$ ) than pre PE treatment values. There is no statistical difference between the reported pain level after the initial series of PE and their current pain on oral immunotherapy ( $P = 0.534$ ).

### IVIG Maintenance

The patient that tested positive for anti-sulfatide antibodies was offered IVIG maintenance therapy given that IVIG is the treatment of choice for this condition (25). This patient's reported a pain reduction from an 8 to a 1 following the initial series of PE. The patient was placed on IVIG (one treatment, 90 grams every 3 weeks) and the pain level has remained at a 1 for the last 6 months.

### No Maintenance Treatment

The remaining 9 patients elected not to continue PE. The 3 non-responders discontinued PE due to lack of efficacy. The pain level in these patients remains unchanged. One patient found that the pain relief

from PE was short lived and also decided to discontinue treatment. The other 5 patients chose to discontinue PE because it was difficult for them to comply with the treatment regimen. The pain level in these 5 patients gradually (over 6 weeks) returned to pre-treatment values. Fig. 5 shows the post PE treatment for all patients.

### Adverse Effects

The patients that underwent a skin biopsy developed no complications from the procedure. None of the patients had any complications during the catheter placement. However, the surgical procedure caused pain in every patient but it usually subsided by the third day. The pain was treated with intravenous (IV) ketorolac (30 mg every 6 hours as needed). During the PE, patients had no major complications. Minor complications were managed by the staff at the PE suite (symptoms of low calcium, hypotension, symptoms of hypoglycemia, and hyper-somnolence) with simple non-invasive interventions.

### DISCUSSION

We treated 33 CRPS patients with PE and found that a series of PE performed over a 2 to 3 week period can significantly reduce pain levels. We chose an initial series of 7 PE treatments to achieve a decrease in plas-



ma fibrinogen levels of at least 30% based on a study of Guillain-Barre patients in which a decrease in fibrinogen of less than 30% correlated with non-resolution of symptoms (26). However, recent evidence suggests that a longer initial PE series may be required in some CRPS patients (27). We also showed that in many of these patients the reduction in pain following the series of PE treatments can be maintained on either a weekly PE schedule, IVIG, or with other immune modulating drugs. The complications reported by the patients were limited and usually subsided on their own or with minimal intervention. Despite the high pain level, most patients tolerated both the placement and maintenance of the catheter well.

Not all CRPS patients responded to PE. Three patients reported no improvement in their pain and one patient reported short-lasting relief that returned to pre-treatment level within 3 days. The remaining patients reported significant pain reduction that was either maintained with immune modulating therapies, or slowly returned to pre-treatment levels in those that chose not to undergo such treatment.

Our rationale for using PE was based on the recent hypothesis, based on in-vitro experiments, proposing an autoimmune etiology for CRPS (9,12,28) and that IVIG has been shown to be efficacious in some CRPS patients (14,29). The mechanism by which PE reduces pain in CRPS is not known, however, our finding that in one patient, PE was more efficacious at reducing pain than IVIG suggested that, in addition to antibody removal, alteration of other plasma factors may contribute to the improved treatment effect. Besides reduction of serum-antibodies, PE reduces a number of factors known to contribute to neuropathic pain such as inflammatory cytokines and fibrinogen; PE can also increase serum anti-inflammatory cytokines (26,30-32).

The efficacy of PE could be due in part to alteration of plasma cytokine levels. Following trauma, mast cells, neutrophils, and macrophages are activated and recruited to the site of injury (33). Disruption of the blood nerve barrier (BNB) allows for the invasion of the nerve by fibroblasts, macrophages, and Schwann cells (34). These cells release pro-inflammatory cytokines and chemokines that have been implicated in the generation of neuropathic pain (35-37). We have shown that plasma levels of chemokines, cytokines, and their soluble receptors are significantly increased in CRPS patients as compared to healthy controls (38). PE has been shown to decrease plasma pro-inflammatory cytokines (30-32), as well as increase the anti-inflammatory cytokine IL-10 (32).

The efficacy of PE could also be due to reduction of plasma fibrinogen. We found a significant correlation ( $P < 0.01$ ) between the reduction of plasma fibrinogen following PE and pain relief. Fibrinogen is a glycoprotein found in blood that is involved in the formation of blood clots and also plays an important role in inflammation (39). Fibrinogen activates macrophages through CD11b/CD18 and toll-like receptor 4 (TLR4) (40). TLR4 is also expressed on nociceptive neurons and its activation results in neuronal sensitization (41). Fibrinogen extravasation into the nervous system has been reported following barrier dysfunction (42,43).

Peripheral nerve injury results in disruption of the BNB and has been implicated in the disruption of the blood spinal cord barrier (BSCB) (43,44). Following barrier disruption, fibrinogen entry into peripheral nerves results in mechanical allodynia whereas extravasation of fibrinogen into the central nervous system (CNS) results in microglia activation and neuroinflammation (42,43). Activated microglia have been shown to be necessary for the initiation of neuropathic pain (45,46). We have shown activated microglia in spinal cord autopsy tissue from a patient with CRPS (47).

In addition, the efficacy of PE could be due to alterations in plasma microRNA (miRNA). We recently reported that blood miRNA profiles differed in CRPS patients compared to healthy controls and that dysregulation of specific miRNAs correlates to symptoms and comorbidities associated with the disease (48). Exosomes are small vesicles that contain diverse classes of miRNAs, mRNAs, proteins, and lipids that are co-expressed, packaged, and secreted from cells into bodily fluids under normal and disease states (49-52). We have also reported that many of the miRNAs that are dysregulated in blood of CRPS patients are associated with exosomes and identified 127 miRNAs whose exosomal concentration were significantly different between CRPS patients and healthy controls (53). One of these miRNAs, miR-29, has been implicated in hereditary neuropathies and several are known to contribute to neuropathic pain (54,55).

The major limitation of this study is its retrospective nature which includes non-randomization, non-blinding, and an uncontrolled design. Not all patients agreed to undergo QST or skin punch biopsy due to fear the procedure would exacerbate their condition. In addition, the only patients that we treated with PE were those whose health insurance carrier considered PE an eligible procedure for their medical condition. This included CRPS patients with a SFN, confirmed by

skin biopsy, or CRPS patients that qualify for Medicare. Due to this limitation, the patients in this study presented with a clinical picture suggestive of a SFN and our findings did not address whether PE is efficacious in all CRPS patients.

In our previous studies, CRPS patients did not respond equally to the same medications (56-58). We have found no agent to be universally efficacious in the treatment of CRPS. Our working hypothesis is that CRPS is composed of different subtypes resulting from more than one etiology and no one treatment is efficacious in all patients. Therefore, the fact that some patients in this study did not respond to PE is consistent with our previous findings.

## CONCLUSIONS

Our study shows that PE is effective in a subset of patients with severe long-standing CRPS. We also

showed that in many of these patients the reduction in pain following the initial series of PE treatments can be maintained on either a weekly PE schedule, IVIG, or with other immune modulating drugs. In addition, this study suggests that patients with the greatest loss of small fibers and temperature sensory deficits are the most likely to benefit from PE therapy. Randomized, placebo controlled studies may be required to confirm and expand our results. Additional studies are needed to explore the mechanisms by which PE and other immune therapies reduce pain in all or a subset of CRPS patients. The data obtained from such studies may aid in advancing our understanding of the mechanisms involved in the pathophysiology of CRPS. A better understanding of these mechanisms may lead to new therapies for this severe life-altering condition.

## REFERENCES

- Schwartzman RJ, Erwin KL, Alexander GM. The natural history of complex regional pain syndrome. *Clin J Pain* 2009; 25:273-80.
- Costigan M, Scholz J, Woolf CJ. Neuro-pathic pain: A maladaptive response of the nervous system to damage. *Annu Rev Neurosci* 2009; 32:1-32.
- Watkins LR, Maier SF. Immune regulation of central nervous system functions: From sickness responses to pathological pain. *J Intern Med* 2005; 257:139-155.
- Cossins L, Okell RW, Cameron H, Simpson B, Poole HM, Goebel A. Treatment of complex regional pain syndrome in adults: A systematic review of randomized controlled trials published from June 2000 to February 2012. *Eur J Pain* 2013; 17:158-173.
- Forouzanfar T, Köke AJ, van Kleef M, Weber WE. Treatment of complex regional pain syndrome type I. *Eur J Pain* 2002; 6:105-122.
- Rowbotham MC. Pharmacologic management of complex regional pain syndrome. *Clin J Pain* 2006; 22:425-429.
- Oaklander AL, Fields HL. Is reflex sympathetic dystrophy/complex regional pain syndrome type I a small-fiber neuropathy? *Ann Neurol* 2009; 65:629-638.
- Kharkar S, Venkatesh YS, Grothusen JR, Rojas L, Schwartzman RJ. Skin biopsy in complex regional pain syndrome: case series and literature review. *Pain Physician* 2012; 15:255-266.
- Blaes F, Schmitz K, Tschernatsch M, Kaps M, Krasenbrink I, Hempelmann G, Bräu ME. Autoimmune etiology of complex regional pain syndrome. *Neurology* 2004; 63:1734-1736.
- Goebel A, Stock M, Deacon R, Sprotte G, Vincent A. Intravenous immunoglobulin response and evidence for pathogenic antibodies in a case of complex regional pain syndrome 1. *Ann Neurol* 2005; 57:463-464.
- Goebel A, Vogel H, Caneris O, Bajwa Z, Clover L, Roewer N, Schedel R, Karch H, Sprotte G, Vincent A. Immune responses to *Campylobacter* and serum autoantibodies in patients with complex regional pain syndrome. *J Neuroimmunol* 2005; 162:184-189.
- Goebel A, Blaes F. Complex regional pain syndrome, prototype of a novel kind of autoimmune disease. *Autoimmun Rev* 2013; 12:682-686.
- Tekus V, Hajna Z, Borbely E, Markovics A, Bagoly T, Szolcsanyi J, Thompson V, Kemény Á, Helyes Z, Goebel A. A CRPS-IgG-transfer-trauma model reproducing inflammatory and positive sensory signs associated with complex regional pain syndrome. *Pain* 2014; 155:299-308.
- Goebel A, Baranowski A, Maurer K, Ghiai A, McCabe C, Ambler G. Intravenous immunoglobulin treatment of the complex regional pain syndrome: A randomized trial. *Ann Intern Med* 2010; 152:152-158.
- Jann S, Francia A, Fruguglietti ME, De Toni Franceschini L, Sterzi R. Efficacy and safety of intravenous immunoglobulin as adjuvant treatment for refractory neuropathic pain. Results of an open-label, multicenter study. *Pain Med* 2012; 13:1334-1341.
- Oaklander AL, Klein MM. Evidence of small-fiber polyneuropathy in unexplained, juvenile-onset, widespread pain syndromes. *Pediatrics* 2013; 131:e1091-e1100.
- Dyck P, Low PA, Windebank AJ, Jaradeh SS, Gosselin S, Bourque P, Smith BE, Kratz KM, Karnes JL, Evans BA, Pineda AA, O'Brien PC, Kyle RA. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. *NEJM* 1991; 325:1482-1486.
- Harden RN, Bruehl S, Perez RS, Birklein F, Marinus J, Maihofner C, Lubenow T, Buvaendran A, Mackey S, Graciosa J,

- Mogilevski M, Ramsden C, Chont M, Vatine JJ. Validation of proposed diagnostic criteria (the "Budapest Criteria") for complex regional pain syndrome. *Pain* 2010; 150:268-274.
19. Dworkin RH, Turk DC, Revicki DA, Harding G, Coyne KS, Peirce-Sandner S, Bhagwat D, Everton D, Burke LB, Cowan P, Farrar JT, Hertz S, Max MB, Rappaport BA, Melzack R. Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2). *Pain* 2009; 144:35-42.
  20. Grothusen JR, Alexander G, Erwin K, Schwartzman R. Thermal pain in complex regional pain syndrome type I. *Pain Physician* 2014; 17:71-79.
  21. Dabby R, Vaknine H, Gilad R, Djaldetti R, Sadeh M. Evaluation of cutaneous autonomic innervation in idiopathic sensory small-fiber neuropathy. *J Peripher Nerv Syst* 2007; 12:98-101.
  22. Gibbons CH, Illigens BM, Wang N, Freeman R. Quantification of sweat gland innervation: A clinical-pathologic correlation. *Neurology* 2009; 72:1479-1486.
  23. Kennedy WR et al. In: Dyck PJ, Thomas PK (eds). *Peripheral Neuropathy*. 4th ed. WB Saunders, Philadelphia, 2004, pp 869-895.
  24. Lauria G, Cornblath DR, Johansson O, McArthur JC, Mellgren SI, Nolano M, Rosenberg N, Sommer C; European Federation of Neurological Societies. EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. *Eur J Neurol* 2005; 12:747-758.
  25. Kornberg AJ, Pestronk A. Antibody-associated polyneuropathy syndromes: Principles and treatment. *Semin Neurol* 2003; 23:181-190.
  26. Sanjay R, Flanagan J, Sodano D, Gorson KC, Ropper AH, Weinstein R. The acute phase reactant, fibrinogen, as a guide to plasma exchange therapy for acute Guillain-Barré syndrome. *J Clin Apher* 2006; 21:105-110.
  27. Goebel A, Jones S, Oomman S, Callaghan T, Sprotte G. Treatment of longstanding complex regional pain syndrome with therapeutic plasma exchange; a preliminary case series of patients treated 2008-2014. *Pain Medicine* 2014; 15:2163-2164.
  28. Kohr D, Singh P, Tschernatsch M, Kaps M, Pouokam E, Diener M, Kummer W, Birklein F, Vincent A, Goebel A, Wallukat G, Blaes F. Autoimmunity against the  $\beta_2$  adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. *Pain* 2011; 152:2690-2700.
  29. Tamburin S, Borg K, Caro XJ, Jann S, Clark AJ, Magrinelli F, Sobue G, Werhagen L, Zanette G, Koike H, Späth PJ, Vincent A, Goebel A. Immunoglobulin G for the treatment of chronic pain: Report of an expert workshop. *Pain Med* 2014; 15:1072-1082.
  30. Gårdlund B, Sjölin J, Nilsson A, Roll M, Wickerts CJ, Wretling B. Plasma levels of cytokines in primary septic shock in humans: Correlation with disease severity. *J Infect Dis* 1995; 172:296-301.
  31. Sadeghi M, Daniel V, Wang H, Zeier M, Schemmer P, Mehrabi A, Lahdou I, Morath C, Opelz G. Plasmapheresis adjusts inflammatory responses in potential kidney transplant recipients. *Transplantation* 2013; 95:1021-1029.
  32. Yeh JH, Wang SH, Chien PJ, Shih CM, Chiu HC. Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis. *Eur J Neurol* 2009; 16:1318-1322.
  33. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. *Nat Rev Neurosci* 2005; 6:521-532.
  34. McMahon SB, Cafferty WB, Marchand F. Immune and glial cell factors as pain mediators and modulators. *Exp Neurol* 2005; 192:444-462.
  35. Abbadie C. Chemokines, chemokine receptors and pain. *Trends Immunol* 2005; 26:529-534.
  36. DeLeo JA, Colburn RW, Nichols M, Malhotra A. Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. *J Interferon Cytokine Res* 1996; 16:695-700.
  37. Watkins LR, Maier SF. Glia: A novel drug discovery target for clinical pain. *Nat Rev Drug Discov* 2003; 2:973-985.
  38. Alexander GM, Peterlin BL, Perreault MJ, Grothusen JR, Schwartzman RJ. Changes in plasma cytokines and their soluble receptors in complex regional pain syndrome. *J Pain* 2012; 13:10-20.
  39. Adams RA, Schachtrup C, Davalos D, Tsigelny I, Akassoglou K. Fibrinogen signal transduction as a mediator and therapeutic target in inflammation: Lessons from multiple sclerosis. *Curr Med Chem* 2007; 14:2925-2936.
  40. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. *J Immunol* 2001; 167:2887-2894.
  41. Wadachi R, Hargreaves KM. Trigeminal nociceptors express TLR-4 and CD14: A mechanism for pain due to infection. *J Dent Res* 2006; 85:49-53.
  42. Davalos D, Ryu JK, Merlini M, Baeten KM, Le Moan N, Petersen MA, Deerinck TJ, Smirnoff DS, Bedard C, Hakoziaki H, Gonias Murray S, Ling JB, Lassmann H, Degen JL, Ellisman MH, Akassoglou K. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. *Nat Commun* 2012; 3:1227.
  43. Lim TK, Shi XQ, Martin HC, Huang H, Luheshi G, Rivest S, Zhang J. Blood-nerve barrier dysfunction contributes to the generation of neuropathic pain and allows targeting of injured nerves for pain relief. *Pain* 2014; 155:9549-67.
  44. Echeverry S, Shi XQ, Rivest S, Zhang J. Peripheral nerve injury alters blood-spinal cord barrier functional and molecular integrity through a selective inflammatory pathway. *J Neurosci* 2011; 31:10819-10828.
  45. Smith HS. Activated microglia in nociception. *Pain Physician* 2010; 13:295-304.
  46. Wang D, Couture R, Hong Y. Activated microglia in the spinal cord underlies diabetic neuropathic pain. *Eur J Pharmacol* 2014; 728:59-66.
  47. Del Valle L, Schwartzman RJ, Alexander G. Spinal cord histopathological alterations in a patient with longstanding complex regional pain syndrome. *Brain Behavior and Immunity* 2009; 23:85-91.
  48. Orlova IA, Alexander GM, Qureshi RA, Sacan A, Graziano A, Barrett JE, Schwartzman RJ, Ajit SK. MicroRNA modulation in complex regional pain syndrome. *J Trans Med* 2011; 9:195.
  49. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. *J Cell Sci* 2000; 113:3365-3374.
  50. Record M, Subra C, Silvente-Poirot S, Poirot M. Exosomes as intercellular signalosomes and pharmacological effectors. *Biochem Pharmacol* 2011; 81:1171-1182.
  51. They C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. *Nat Rev Immunol* 2009; 9:581-593.
  52. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol* 2007; 9:654-659.

53. McDonald MK, Tian Y, Qureshi RA, Gormley M, Ertel A, Gao R, Aradillas Lopez E, Alexander GM, Sacan A, Fortina P, Ajit SK. Functional significance of macrophage-derived exosomes in inflammation and pain. *Pain* 2014; 155:1527-1539.
54. Kynast KL, Russe OQ, Geisslinger G, Niederberger E. Novel findings in pain processing pathways: Implications for miRNAs as future therapeutic targets. *Expert Rev Neurother* 2013; 13:515-525.
55. Verrier JD, Lau P, Hudson L, Murashov AK, Renne R, Notterpek L. Peripheral myelin protein 22 is regulated post-transcriptionally by miRNA-29a. *Glia* 2009; 57:1265-1279.
56. Schwartzman RJ, Chevlen E, Bengtson K. Thalidomide has activity in treating complex regional pain syndrome. *Arch Intern Med* 2003; 163:1487-1488.
57. Schwartzman RJ, Patel M, Grothusen JR, Alexander GM. Efficacy of 5-day continuous lidocaine infusion for the treatment of refractory complex regional pain syndrome. *Pain Med* 2009; 10:401-412.
58. Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: A double-blind placebo controlled study. *Pain* 2009; 147:107-115.